~~<i id='6AC8B6040F'><strike id='6AC8B6040F'><tt id='6AC8B6040F'><pre id='6AC8B6040F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：explore 2025-09-29 18:17:33 - browse：1

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Shingles, which affected Dianne Feinstein, is on the rise

entertainment

leisure time

entertainment

focus

hotspot

focus

Sen.BillCassidy(R-La.)StefaniReynolds/TheNewYorkTimesviaAPWASHINGTON—Thetop-rankingRepublicanontheSe

WSS

Would Medicare drug price negotiations stall in a shutdown?

New brain studies show LSD's effects on the brain in full color

Health tech startups drop sharply from 2021 highs

Inequities make cancer less preventable for women: report

Think you might have Covid

How the Dana

explore

Wikipedia

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Virtual Event: How to Increase Diversity in Clinical Trials

New air purifier tech could be key to improving indoor air quality

Menendez indictment could see pharma lose a key ally

Medical leaders decry Supreme Court decision on affirmative action

FDA seeks to regulate lab

What does generative AI mean for health care? We asked experts

Medicare Advantage today, explained in one chart

Drug repurposing or repositioning? The language matters

Intercept Pharmaceuticals sells itself for less than $1 billion

leisure time

Eli Lilly, Pfizer, and others want in on the online prescription market

FDA advisers vote against ALS treatment from BrainStorm

Why do women spend more than men on medical expenses?

Independent physicians launch a new lobbying group

Medicare drug price negotiation program allowed for now

Biotech venture capitalists face new demands from investors

entertainment

focus

hotspot

focus